Market news

Lisa Pitt, Pharm.D., M.S.J. appointed Senior Vice President, Regulatory Affairs Shiguang Liu, M.D., Ph.D. appointed Vice President, Clinical Development REDWOOD CITY, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced the appointments of Lisa Pitt, Pharm.D., M.S.J. as Senior Vice President, Regulatory

REDWOOD CITY, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today announced that management will participate at the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York, NY. H.C. Wainwright 28th Annual Global Investment ConferencePresentation Date/Time: Wednesda

Jasper Therapeutics Inc. (NASDAQ:JSPR) reported better-than-expected second-quarter 2026 results on Monday, although shares of the clinical-stage biotechnology company fell 4.

Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent PIPE financing raising $132 million in gross proceeds REDWOOD CITY, Calif., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat immune-mediated diseases, today

Jasper Therapeutics (JSPR) has an average rating of overweight and mean price target of $6.62, accor

Detailed price information for Jasper Therapeutics Inc. (JSPR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Jasper Therapeutics Inc. (JSPR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Jasper Therapeutics Inc. (JSPR-Q) from The Globe and Mail including charting and trades.

Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS) shares

The acquisition, which involves a concurrent licensing deal with startup Mirador, gives Jasper a chance to rebound from setbacks that have wiped out most of its market value.

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven...